Details of the Drug

General Information of Drug (ID: DMWK679)

Drug Name

OMP-18R5

Synonyms

Vantictumab; Wnt inhibitors (mAb, cancer), OncoMed Pharmaceuticals

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
------------------------------------------------------------------------------------

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT01345201) A Dose Escalation Study of OMP-18R5 in Subjects With Solid Tumors. U.S. National Institutes of Health.
2	Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012 Jul 17;109(29):11717-22.